Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Mark D
MD
Gonzalez
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Meghan A
MA
Wallace
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Tiffany
T
Hink
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Erik R
ER
Dubberke
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA cburnham@path.wustl.edu.
Carey-Ann D
http://orcid.org/0000-0002-1137-840X
CA
Burnham
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D010802:Phylogeny; D000078142:Tazobactam
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam